Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  JAMA psychiatry

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamapsychiatry.2016.0109PMID 27049826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction

  2015cited by this paper
• History of Treatment Access and Drug Use among Participants in a Trial Testing Injectable Opioids under Supervision for Long-Term Heroin Injectors

  2015cited by this paper
• The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency

  2015cited by this paper
• Efficacy of Heroin-Assisted Treatment in Belgium: A Randomised Controlled Trial

  2015cited by this paper
• Using multiple imputation to deal with missing data and attrition in longitudinal studies with repeated measures of patient-reported outcomes

  2015cited by this paper
• Canada in breach of ethical standards for clinical trials

  2014cited by this paper
• Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone

  2014cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2014cited by this paper
• Incidence of Hydromorphone-Induced Neuroexcitation in Hospice Patients

  2013cited by this paper
• Hydromorphone: evolving to meet the challenges of today's health care environment.

  2013cited by this paper
• Differences between opioids: pharmacological, experimental, clinical and economical perspectives

  2013cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• New heroin-assisted treatment: Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond

  2012cited by this paper
• Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment

  2012cited by this paper
• Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.

  2011cited by this paper
• The role of hydromorphone in cancer pain treatment: a systematic review

  2011cited by this paper
• Heroin maintenance for chronic heroin-dependent individuals.

  2011cited by this paper
• Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.

  2010cited by this paper
• Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial.

  2010cited by this paper
• Diacetylmorphine versus methadone for the treatment of opioid addiction.

  2009cited by this paper
• The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia

  2008cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2008cited by this paper
• Heroin-assisted treatment for opioid dependence: randomised controlled trial.

  2007cited by this paper
• Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

  2006cited by this paper
• Controlled trial of prescribed heroin in the treatment of opioid addiction.

  2006cited by this paper
• Non‐inferiority trials: the ‘at least as good as’ criterion with dichotomous data

  2006cited by this paper
• Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial.

  2006cited by this paper
• Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials

  2006cited by this paper
• Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence.

  2005cited by this paper
• Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials

  2005cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2003cited by this paper
• Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials (vol 327, pg 310, 2003)

  2003cited by this paper
• Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics

  2002cited by this paper
• Non‐inferiority trials: the ‘at least as good as’ criterion

  2002cited by this paper
• The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome.

  1998cited by this paper
• Self-report among injecting drug users: a review.

  1998cited by this paper
• Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments

  1998cited by this paper
• An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation--a VA cooperative study.

  1996cited by this paper

• Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review.

  2026cites this paper
• Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy.

  2026cites this paper
• Operational and clinical procedures of heroin-assisted treatment in Switzerland: a nation-wide survey study

  2025cites this paper
• “We need all hands on deck”: characterizing addiction medicine training in Canada—a mixed methods study of fellowship program directors

  2025cites this paper
• Experiences of Healthcare Professionals Working in Injectable Opioid Agonist Treatment Programs

  2025cites this paper
• Approved medications for opioid use disorder : current update

  2025cites this paper
• A sea of need: provider accounts of strategies used to manage admission demands to safer opioid supply programs in Ontario

  2025cites this paper
• Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis

  2025cites this paper
• Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience

  2025cites this paper
• Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants

  2025cites this paper
• Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short‐Acting Injectable Opioid Treatment in Australia

  2025cites this paper
• A scoping review and concept analysis to inform Canada's safe(r) opioid supply research agenda.

  2025cites this paper
• Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysis.

  2025cites this paper
• Trends in accidental drug overdose mortality in Canada: An analysis from 1974 to 2023.

  2025cites this paper
• Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada

  2025cites this paper
• Perspectives on prescribed safer supply programs among people who inject drugs in Baltimore, Maryland: A mixed methods study among individuals highly affected by drug toxicity.

  2025cites this paper
• Community Pharmacy‐Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program

  2025cites this paper
• Management of treatment-refractory opioid use disorder: a case-series of a modified maintenance protocol.

  2025cites this paper
• Historical and contextual variation in daily opioid consumption rates: implications for supply control, service delivery, and research

  2025cites this paper
• Risk factors for multiple skin abscesses among community-recruited people who inject drugs in Los Angeles, CA, and Denver, CO: a cross-sectional study

  2025cites this paper
• Repurposing prescribed hydromorphone: Alternative uses of safer supply and tablet-injectable opioid agonist treatment to meet unaddressed health needs.

  2024cites this paper
• Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.

  2024cites this paper
• Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists

  2024cites this paper
• Mapping a moral panic: News media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada.

  2024cites this paper
• Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey

  2024cites this paper
• Implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia: A mixed methods study

  2024cites this paper
• "The machine doesn't judge": Counternarratives on surveillance among people accessing a safer opioid supply via biometric machines.

  2024cites this paper
• Predictors of retention in heroin-assisted treatment in Denmark 2010-2018 - A record-linkage study.

  2024cites this paper
• Perinatal injectable opioid agonist therapy (iOAT) treatment experience: A qualitative study

  2024cites this paper
• “It’s a delicate balance”: clinicians’ experiences of providing heroin-assisted treatment

  2024cites this paper
• "I'm just searching to get better": Constructions of treatment citizenship on injectable opioid agonist treatment.

  2024cites this paper
• Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses

  2024cites this paper
• Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

  2024cites this paper
• Clinicians’ Perspectives and an Ethical Analysis of Safer Supply Opioid Prescribing

  2024influential citation
• Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada

  2024cites this paper
• Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review

  2023cites this paper
• Community partner perspectives on the implementation of a novel safer supply program in Canada: a qualitative study of the MySafe Project

  2023cites this paper
• Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: A context-focused systematic review.

  2023cites this paper
• Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies

  2023cites this paper
• “As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises

  2023cites this paper
• Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment

  2023cites this paper
• Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

  2023cites this paper
• Iteration is not solving the opioid crisis, it’s time for transformation

  2023cites this paper
• A Call for an Evidence-Based Strategy Against the Overdose Crisis

  2023cites this paper
• Strategies to Reduce Harm: An Expert Panel Discussion on the Fentanyl Crisis

  2023cites this paper
• A qualitative assessment of tablet injectable opioid agonist therapy (TiOAT) in rural and smaller urban British Columbia, Canada: Motivations and initial impacts.

  2023cites this paper
• Experiences of serious depression and serious anxiety among clients receiving injectable Opioid Agonist Treatment (iOAT)

  2023cites this paper
• Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study

  2023cites this paper
• Guideline No. 443a: Opioid Use Throughout Women's Lifespan: Fertility, Contraception, Chronic Pain, and Menopause.

  2023cites this paper
• Opioid-related deaths in Kingston, Frontenac, Lennox and Addington in Ontario, Canada: the shadow epidemic.

  2023cites this paper
• Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark.

  2023cites this paper
• Public support for safer supply programs: analysis of a cross-sectional survey of Canadians in two provinces

  2023cites this paper
• Directive clinique no 443a : Opioïdes aux différentes étapes de la vie des femmes : Fertilité, contraception, douleur chronique et ménopause.

  2023cites this paper
• Directive clinique no 443b : Opioïdes aux différentes étapes de la vie des femmes : Grossesse et allaitement.

  2023cites this paper
• The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC

  2023cites this paper
• High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants

  2023cites this paper
• Guideline No. 443b: Opioid Use Throughout Women's Lifespan: Opioid Use in Pregnancy and Breastfeeding.

  2023cites this paper
• Narkotikapolitikk i endring: Heroinklinikkenes oppkomst i Norge

  2023cites this paper
• “They Talk to Me Like a Person” Experiences of People in an Injectable Opioid Agonist Treatment Program

  2023cites this paper
• A Case report of a continuous ambulatory drug delivery (CADD) pump to deliver opioid agonist treatment in an acute care setting

  2023cites this paper
• Patients’ satisfaction with heroin-assisted treatment: a qualitative study

  2023cites this paper
• Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study

  2023cites this paper
• 'I don't chase drugs as much anymore, and I'm not dead': Client reported outcomes associated with safer opioid supply programs in Ontario, Canada.

  2023cites this paper
• First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada

  2023cites this paper
• “It feels like I’m coming to a friend’s house”: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre)

  2023cites this paper
• Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.

  2022cites this paper
• Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada

  2022cites this paper
• A concept mapping study of service user design of safer supply as an alternative to the illicit drug market.

  2022cites this paper
• Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario

  2022cites this paper
• Opioid Use Disorder

  2022cites this paper
• Diacetylmorphine for Adults With Opioid Dependence

  2022cites this paper
• Opium tincture versus methadone for opioid agonist treatment: A randomized controlled trial.

  2022cites this paper
• Dealing with the epidemic of endocarditis in people who inject drugs.

  2022cites this paper
• A low-barrier, flexible safe supply program to prevent deaths from overdose

  2022cites this paper
• Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).

  2022cites this paper
• Switzerland’s Dependence on a Diamorphine Monopoly

  2022cites this paper
• Prescribing safe supply: ethical considerations for clinicians

  2022cites this paper
• Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada

  2022cites this paper
• Confronting Canada’s overdose crisis: what’s the deal with decriminalization?

  2022cites this paper
• Investigating opioid preference to inform safe supply services: A cross sectional study.

  2022cites this paper
• Implementing injectable opioid agonist treatment: a survey of professionals in the field of opioid use disorders

  2022cites this paper
• Case report: acute care management of severe opioid withdrawal with IV fentanyl

  2022cites this paper
• Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

  2022cites this paper
• Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths.

  2022cites this paper
• Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review

  2022cites this paper
• Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness

  2022cites this paper
• Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

  2022cites this paper
• Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.

  2022cites this paper
• Factors associated with 60-day adherence to “safer supply” opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency

  2022cites this paper
• Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs

  2022cites this paper
• A Student-Driven Advocacy Project to Address the Opioid Crisis in Canada: Implications for Developing Competency in Health Advocacy During Medical Training

  2021cites this paper
• Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran.

  2021cites this paper
• Cost-Effectiveness and Guidelines for Opioid Substitution Treatment

  2021cites this paper
• Why Integrating Medications and Psychosocial Interventions is Important to Successfully Address the Opioid Crisis in Canada

  2021cites this paper
• Increasing Preference for Fentanyl among A Cohort of People who Use Opioids in Vancouver, Canada, 2017-2018

  2021cites this paper
• Does Heroin-Assisted Treatment Reduce Crime? A Review of Randomized-Controlled Trials.

  2021cites this paper
• A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research.

  2021cites this paper
• New Approaches in Drug Dependence: Opioids

  2021cites this paper
• Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with injectable opioid agonist treatment patients

  2021cites this paper
• Supporting Any Positive Change: Harm Reduction as an Integral Pillar of Opioid Use Disorder Treatment

  2021cites this paper